View ValuationMore Impact 将来の成長Future 基準チェック /06現在、 More Impactの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長6.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 26More Impact AG, Annual General Meeting, Aug 04, 2026More Impact AG, Annual General Meeting, Aug 04, 2026, at 11:00 W. Europe Standard Time.New Risk • Dec 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (346% increase in shares outstanding).お知らせ • Jul 15More Impact AG, Annual General Meeting, Aug 21, 2025More Impact AG, Annual General Meeting, Aug 21, 2025, at 11:00 W. Europe Standard Time.お知らせ • Jul 02More Impact AG Announces Supervisory Board ChangesMore Impact AG announced that the Frankfurt District Court has appointed Prof. Dr. Stefan Hegemann as a new member of the Supervisory Board following a proposal by the company. He succeeds Dr. Karsten Behlke, who has resigned from office to move to the operational business of More Impact AG. Prof. Hegemann will stand for election to the Supervisory Board at the company's upcoming Ordinary General Meeting on August 21, 2025. With his long-standing experience as a medical doctor and his comprehensive scientific know-how, Prof. Hegemann will support More Impact in its future growth. He is a honorary professor of the University of Zurich and is also the founder of the renowned "Balance Clinic". Prof. Hegemann was head physician at the Department of Otorhinolaryngology and Facial Surgery of the University Hospital Zurich for several years. He also worked at the Johns Hopkins University in Baltimore and the Karlsbad-Langensteinbach Clinic. He completed his medical studies at the University of Essen, the LMU Munich, the McMaster University Hamilton and the University of Cape Town in South Africa. Prof. Hegemann is a member of the Prosper Menière Society, the Association of German-speaking Audiologists and Neurootologists (ADANO) and the Robert Barány Society. He is also a member of both the German Society for ENT and Neurology, Head and Neck Surgery and the Swiss Society for Otorhinolaryngology, Neck and Facial Surgery. In addition, he has been honoured with several accolades, including the ADANO Innovation Award.New Risk • Apr 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €85.8m (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risk Market cap is less than US$100m (€85.8m market cap, or US$97.9m).お知らせ • Apr 10More Impact AG and BG Braingate Technology GmbH Introduces Z-Boxx as an Innovative Smoking Cessation ProductMore Impact AG and its wholly owned subsidiary BG Braingate Technology GmbH are launching the Z-Boxx. Braingate is thus integrating its patented inhaler technology into a marketable product. The Z-Boxx allows smokers to gradually quit nicotine without having to give up the smoking experience. The Z-Boxx thus makes an active contribution to improving health and also significantly reduces the burden on the environment by avoiding waste. The comprehensive market launch of the innovative product is planned for the fourth quarter of 2025. The Z-Boxx is based on an innovative, patented filter and vaporization technology that heats tobacco instead of burning it. The actual nicotine dosage can be regulated so that the Z-Boxx can be used to continuously reduce the smoker’s nicotine intake – right up to complete nicotine abstinence. In addition, no typical combustion products such as tar or carbon monoxide are produced. The mechanism of action of the Z-Boxx therefore directly addresses the most harmful aspects of smoking. Nevertheless, the smoking experience remains authentic in taste. Compared to disposable e-cigarettes or traditional tobacco products, the Z-Boxx produces no environmentally harmful filter waste, as filterless cigarettes are used and harmful substances are filtered out. According to the WHO, an estimated 4.5 trillion cigarette filters end up in the environment worldwide every year. The battery of the Z-Boxx can also be flexibly removed and recharged, which significantly reduces electronic waste.New Risk • Mar 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €95.2m (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (25% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risk Market cap is less than US$100m (€95.2m market cap, or US$98.7m).New Risk • Sep 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 8x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€27.3m market cap, or US$30.4m).New Risk • Aug 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (€4.02m market cap, or US$4.40m). Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).お知らせ • Jul 23Aee Gold Ag, Annual General Meeting, Aug 29, 2024Aee Gold Ag, Annual General Meeting, Aug 29, 2024, at 11:00 W. Europe Standard Time. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、More Impact は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DUSE:AEE1 - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数アナリストによる今後の成長予測収入対貯蓄率: AEE1の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: AEE1の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: AEE1の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: AEE1の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: AEE1の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AEE1の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/30 20:36終値2026/07/30 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋More Impact AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 26More Impact AG, Annual General Meeting, Aug 04, 2026More Impact AG, Annual General Meeting, Aug 04, 2026, at 11:00 W. Europe Standard Time.
New Risk • Dec 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (346% increase in shares outstanding).
お知らせ • Jul 15More Impact AG, Annual General Meeting, Aug 21, 2025More Impact AG, Annual General Meeting, Aug 21, 2025, at 11:00 W. Europe Standard Time.
お知らせ • Jul 02More Impact AG Announces Supervisory Board ChangesMore Impact AG announced that the Frankfurt District Court has appointed Prof. Dr. Stefan Hegemann as a new member of the Supervisory Board following a proposal by the company. He succeeds Dr. Karsten Behlke, who has resigned from office to move to the operational business of More Impact AG. Prof. Hegemann will stand for election to the Supervisory Board at the company's upcoming Ordinary General Meeting on August 21, 2025. With his long-standing experience as a medical doctor and his comprehensive scientific know-how, Prof. Hegemann will support More Impact in its future growth. He is a honorary professor of the University of Zurich and is also the founder of the renowned "Balance Clinic". Prof. Hegemann was head physician at the Department of Otorhinolaryngology and Facial Surgery of the University Hospital Zurich for several years. He also worked at the Johns Hopkins University in Baltimore and the Karlsbad-Langensteinbach Clinic. He completed his medical studies at the University of Essen, the LMU Munich, the McMaster University Hamilton and the University of Cape Town in South Africa. Prof. Hegemann is a member of the Prosper Menière Society, the Association of German-speaking Audiologists and Neurootologists (ADANO) and the Robert Barány Society. He is also a member of both the German Society for ENT and Neurology, Head and Neck Surgery and the Swiss Society for Otorhinolaryngology, Neck and Facial Surgery. In addition, he has been honoured with several accolades, including the ADANO Innovation Award.
New Risk • Apr 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €85.8m (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risk Market cap is less than US$100m (€85.8m market cap, or US$97.9m).
お知らせ • Apr 10More Impact AG and BG Braingate Technology GmbH Introduces Z-Boxx as an Innovative Smoking Cessation ProductMore Impact AG and its wholly owned subsidiary BG Braingate Technology GmbH are launching the Z-Boxx. Braingate is thus integrating its patented inhaler technology into a marketable product. The Z-Boxx allows smokers to gradually quit nicotine without having to give up the smoking experience. The Z-Boxx thus makes an active contribution to improving health and also significantly reduces the burden on the environment by avoiding waste. The comprehensive market launch of the innovative product is planned for the fourth quarter of 2025. The Z-Boxx is based on an innovative, patented filter and vaporization technology that heats tobacco instead of burning it. The actual nicotine dosage can be regulated so that the Z-Boxx can be used to continuously reduce the smoker’s nicotine intake – right up to complete nicotine abstinence. In addition, no typical combustion products such as tar or carbon monoxide are produced. The mechanism of action of the Z-Boxx therefore directly addresses the most harmful aspects of smoking. Nevertheless, the smoking experience remains authentic in taste. Compared to disposable e-cigarettes or traditional tobacco products, the Z-Boxx produces no environmentally harmful filter waste, as filterless cigarettes are used and harmful substances are filtered out. According to the WHO, an estimated 4.5 trillion cigarette filters end up in the environment worldwide every year. The battery of the Z-Boxx can also be flexibly removed and recharged, which significantly reduces electronic waste.
New Risk • Mar 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €95.2m (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (25% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risk Market cap is less than US$100m (€95.2m market cap, or US$98.7m).
New Risk • Sep 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 8x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€27.3m market cap, or US$30.4m).
New Risk • Aug 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (€4.02m market cap, or US$4.40m). Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).
お知らせ • Jul 23Aee Gold Ag, Annual General Meeting, Aug 29, 2024Aee Gold Ag, Annual General Meeting, Aug 29, 2024, at 11:00 W. Europe Standard Time.